

ONE HUNDRED TENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM  
2157 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6143

Majority (202) 225-5051  
Minority (202) 225-5074

**WITNESS LIST**

**HEARING ON**

**“FDA’s Role in the Evaluation of Avandia’s Safety”**

**May 4, 2007**

**Panel One**

**Andrew C. von Eschenbach, M.D.**, FDA Commissioner.

**Panel Two**

**Steven Nissen, M.D., F.A.C.C.**, Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic

**Bruce M. Psaty, MD, PhD.**, Co-director of the Cardiovascular Health Research Unit, professor of medicine, epidemiology, and health services at the University of Washington, and an investigator at the Center for Health Studies, Group Health, Seattle, WA

**John B. Buse, MD, PhD.**, Professor at the University of North Carolina School of Medicine in Chapel Hill, North Carolina

**Panel Three**

**Moncef M. Slaoui, PhD.**, Chairman of Research and Development at GlaxoSmithKline